Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

TPMT, UGT1A1 and DPYD: genotyping to ensure safer cancer therapy?

Trends in pharmacological sciences - 1 Aug 2006

Maitland Michael L, Vasisht Kaveeta, Ratain Mark J

Abstract excerpt

The Food and Drug Administration (FDA) has approved label changes for two anticancer drugs, 6-mercaptopurine (6-MP) and irinotecan, to include pharmacogenetic testing as a potential means to reduce the rate of severe toxic events. Comprehensive evaluation of the clinical benefit and cost effectiveness of screening strategies with these tests has not been completed. However, the FDA decided that evidence indicates...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Camptothecin
Share to Dihydrouracil Dehydrogenase (NADP)
Share to Glucuronosyltransferase

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Irinotecan

Share to Mercaptopurine

Share to Methyltransferases

Share to Neoplasms

Share to Pharmacogenetics

Source

Identifiers

PMID: 16815558
DOI: 10.1016/j.tips.2006.06.007

Genes

DPYD
TPMT

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

TPMT, UGT1A1 and DPYD: genotyping to ensure safer cancer therapy?PMID 16815558Read ↗

Genotypes Affecting the Pharmacokinetics of Anticancer Drugs.Semantic proximity Read ↗

Precision Medicine: UGT1A1 Genotyping to Better Manage Irinotecan-Induced Toxicity.Semantic proximity Read ↗

Genetic determinants of cancer drug efficacy and toxicity: practical considerations and perspectives.Semantic proximity Read ↗

Cancer pharmacogenomics: SNPs, chips, and the individual patient.Semantic proximity Read ↗

Pharmacogenomics of drug-metabolizing enzymes and drug transporters in chemotherapy.Semantic proximity Read ↗

Pharmacogenetic testing for uridine diphosphate glucuronosyltransferase 1A1 polymorphisms: are we there yet?Semantic proximity Read ↗

Cancer Pharmacogenomics: Powerful Tools in Cancer Chemotherapy and Drug DevelopmentSemantic proximity Read ↗

Advances and challenges in hereditary cancer pharmacogenetics.Semantic proximity Read ↗

PharmFrag: An Easy and Fast Multiplex Pharmacogenetics Assay to Simultaneously Analyze 9 Genetic Polymorphisms Involved in Response Variability of Anticancer Drugs.Semantic proximity Read ↗

[SNPs associated with adverse effects].Semantic proximity Read ↗

Germline oncopharmacogenetics, a promising field in cancer therapy.Semantic proximity Read ↗

Pharmacogenetic approach for cancer treatment-tailored medicine in practice.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.